ounting evidence has associated a pathological increase in left ventricular (LV) mass with higher rates of cardiovascular morbidity and mortality even after adjustment for potential confounders. [1][2][3] Evidence stemming from meta-analyses and randomized trials suggests that angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are more effective in reversing LV hypertrophy (LVH) than other antihypertensive therapies and are associated with improved clinical outcomes, independent of blood pressure control. [4] [5] [6] These studies suggest that LVH is an independent, modifiable, and potentially overlooked risk factor, with management implications more complex than simply maintaining effective blood pressure control. Therefore, screening for LVH may be a valuable target in the effort to improve cardiovascular outcomes.
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ounting evidence has associated a pathological increase in left ventricular (LV) mass with higher rates of cardiovascular morbidity and mortality even after adjustment for potential confounders. [1] [2] [3] Evidence stemming from meta-analyses and randomized trials suggests that angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are more effective in reversing LV hypertrophy (LVH) than other antihypertensive therapies and are associated with improved clinical outcomes, independent of blood pressure control. [4] [5] [6] These studies suggest that LVH is an independent, modifiable, and potentially overlooked risk factor, with management implications more complex than simply maintaining effective blood pressure control. Therefore, screening for LVH may be a valuable target in the effort to improve cardiovascular outcomes.
LVH screening is hindered by low disease prevalence, poor test characteristics of electrocardiography (ECG)-based detection methods, 7 and the high cost of universal screening with transthoracic echocardiography. 8 Amino-terminal B-type natriuretic peptide (NT-proBNP) and cardiac troponin T (cTnT) are validated biomarkers associated with LVH [9] [10] [11] and have test characteristics complementary to the ECG; adding these assays to the ECG may improve LVH screening, especially in subgroups such as the obese, where the prevalence of LVH is high and ECG criteria perform poorly.
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by Sokolow-Lyon (S-L) ECG criteria; (2) NT-proBNP in the top sex-specific quartile; and (3) detectable cTnT using a highly sensitive assay. Using cardiac magnetic resonance imaging (MRI)-determined LVH as the primary outcome, we characterized the performance of each test and the combined LVH risk score.
Methods

Study Group
The DHS is a probability-based population sample of 6101 Dallas County residents ages 18 to 65 years. Details of the study design and participant selection have been described previously. 13 Blacks were intentionally oversampled to compose 50% of the DHS cohort. All of the participants provided written informed consent, and the study was approved by the institutional review board of the University of Texas Southwestern Medical Center. We included all subjects who participated in all 3 phases of DHS data collection, including cardiac magnetic resonance imaging (n=2501). We excluded 23 subjects with myocardial infarction, heart failure, coronary artery bypass graft surgery, percutaneous coronary intervention, ischemic cerebrovascular disease, bundle branch block, or Q-wave evidence of previous myocardial infarction, because these could interfere with the interpretation of LVH criteria by ECG or prompt cardiac imaging. No subjects had atrial fibrillation on their 12-lead ECG. This left a final sample of 2478 subjects for the present analysis.
MRI and ECG
ECG-gated cine magnetic resonance images were obtained from 2 comparable 1.5-T MRI systems (Philips Medical Systems, Best, The Netherlands). Standard 12-lead ECGs were recorded and interpreted by 2 DHS investigators blinded to demographic and clinical information. We assessed the test characteristics of 4 ECG criteria (S-L voltage criteria, 14 Cornell ECG criteria, 15 Romhilt-Estes ECG criteria, 16 and the Cornell/Strain index 17 ) for detection of LVH in the DHS population.
Biomarker Assays
Based on previous work from our group, we used a well-validated, commercially available NT-proBNP assay (Roche Diagnostics) 18 and chose a cut point of 7.82 pmol/L in women and 3.42 pmol/L in men, which corresponds with the sex-specific 75th percentile in a healthy, phenotypically normal subpopulation of the DHS cohort. 19 We measured cTnT levels using a highly sensitive assay on an automated platform (Roche Diagnostics). Based on previous analyses by our group 11 and others, 10 we used the minimal detectable concentration of the cTnT assay (0.003 μg/L) as our threshold for LVH screening.
Variable Definitions
For this study, cardiac MRI-derived LV mass was indexed to body surface area, and the presence of LVH was defined as at or above the sex-specific 99th percentile (95 g/m 2 in women and 117 g/m 2 in men) of the healthy, phenotypically normal subpopulation of the DHS cohort. 19 This data-derived threshold closely approximates previously published echo-derived cut points shown to be predictors of adverse cardiovascular events 20 and was thus chosen a priori as the outcome for the primary analysis. The components of the LVH risk score were as follows: (1) an ECG that met S-L ECG criteria ([S amplitude in V1 + maximum R amplitude in V5 or V6] > 3.5 mV) 14 ; (2) NT-proBNP greater than the sex-specific 75th percentile 18 ; and (3) detectable cTnT using the high-sensitivity assay. For each participant, an integer LVH risk score ranging from 0 to 3 was calculated by summing the number of above criteria that were met.
Statistical Analysis
The diagnostic performance characteristics of ECG, cTnT, and NT-proBNP were evaluated as separate tests and in combination. We compared the area under the receiver operator characteristic curve (AUC) for the individual and combined tests. Categorical analyses compared differences for individual and combined groups using the Jonckheere-Terpstra test. Stratified analyses using χ 2 and KruskalWallis tests were performed for continuous and categorical variables across sex, ethnicity, hypertension, and body mass index (BMI) categories. 21 We defined number needed to screen as the number of patients who would need to be screened to detect 1 more case of LVH. This was calculated by dividing 1 over the positive predictive value. All of the statistical analyses were performed using SAS version 9.2 (Cary, NC), and 2-sided P values <0.05 were considered significant. Please see the online-only Data Supplement for additional Methods detail.
Results
Study Group
Our cohort (55% women, 47% black, and 29% having hypertension) had a mean±SD age of 44.0±9.6 years and BMI 30.0±7.1 kg/m 2 ( Table 1 ). All of the subjects had an estimated ECG with positive S-L criteria for LVH was seen in 4.8% of participants, cTnT was detectable in 24.3%, and by construction 25.0% had an NT-proBNP in the top sex-specific quartile. Table S1 (available in the online-only Data Supplement) shows the number of patients in each testing group.
Individual Test Performance
The S-L ECG voltage criteria had sensitivity of 26% (95% confidence interval [CI], 17-32%) with specificity of 96% (95% CI, 95-97%) and an AUC of 0.760 (95% CI, 0.716-0.804); the Cornell criteria had a sensitivity of 35% (95% CI, 27-44%) with AUC of 0.738 (95% CI, 0.689-0.788), the Cornell/Strain index criteria had a sensitivity of 44% (95% CI, 36-53%) and an AUC of 0.754 (95% CI, 0.708-0.800). The R-E point score system had lower sensitivity and AUC in our study cohort. We selected the S-L voltage criteria as our ECG standard for LVH because it had the highest AUC and is ubiquitous in clinical practice. Table 2 shows a comparison of the diagnostic characteristics of each ECG criteria tested. Note that the AUC of the S-L criteria was only modestly higher than the Cornell criteria, the Cornell/Strain index criteria, and the Romhilt-Estes ECG criteria in the DHS. Table S2 shows the AUCs of each ECG criteria tested individually, as well as incorporated in the LVH risk score. Because the Cornell/Strain index criteria had the highest sensitivity of the various ECG criteria, we repeated our analysis using this as the alternate ECG comparator; these analyses are shown as Tables S3 to S6. NT-proBNP and cTnT had higher sensitivity (55% [95% CI, 44-61%] and 50% [95% CI, 42-59%], respectively) and lower specificity (72% [95% CI, 76-78%] and 77% [95% CI, 76-79%], respectively) compared with ECG alone (Table 3) . S-L ECG criteria ( Figure 1A ) had a significantly higher falsenegative rate as BMI increased (83% in highest BMI category; P<0.05 for trend), contrasting with cTnT ( Figure 1B ), which had a trend toward a lower rate of false negatives at higher BMI categories but still had high false-negative rates overall (46% in highest cTnT category; P<0.05 for trend); NT-proBNP ( Figure 1C ) remained similar across BMI categories, whereas LVH risk score ≥1 had the lowest false-negative rate of 26% at the highest BMI group ( Figure 1D ). Overall, the highest AUC individual test ( 
Combined Test Performance
A total of 1330 participants (54%) had a score of 0, whereas 1148 (46%) had a score ≥1, 282 (11%) a score ≥2, and 24 (1%) a score of 3. An LVH risk score ≥1 offered higher sensitivity (76% [95% CI, 67.4-82.5%]) than any individual test, with moderate specificity (55% [95% CI, 52.7-61.2%]), whereas LVH risk scores ≥2 or 3 had progressively higher specificities (90% and 99% respectively) with lower sensitivities (44% and 9% respectively). All of the testing groups had a very high negative predictive value (≥95%; Table 3 Figure 2 ). The combination of both biomarkers without ECG had a significantly lower AUC than ECG alone (0.623 vs 0.760; P<0.0001). Stratified analyses showed that the observed improvements in AUC over ECG alone were statistically significant in subjects older than 50 years, men, black subjects, and in those with hypertension. We also observed a consistent and significant improvement across BMI categories (Table 4) .
LVH Risk Score Diagnostic Efficiency
The probability of having LVH increased markedly from 2% in those with an LVH risk score of 0 to 50% in those with an LVH risk score of 3 (P<0.0001), although the absolute number of people with a risk score of 3 was small ( Figure 3A) .
The number needed to screen to detect 1 case of LVH was 50 in the group with LVH risk score of 0, 11 for those with score ≥1, 5 for a score ≥2, and 2 for a score of 3. The association of the score with the presence of LVH became more pronounced at higher BMI categories (P<0.05 for trend; Figure 3B ). In our cohort, the triple test strategy picked up more LVH cases than any individual test, including 71 additional LVH cases over ECG alone, with notable improvement in sensitivity for groups where the prevalence of LVH is high; these include those aged >50 years, men, blacks, and subjects with hypertension or obesity (Table 5) .
Discussion
The ECG is the least expensive and most widely available method for the detection of LVH; however, several studies have shown the various ECG criteria perform poorly as a screening test. A 2007 meta-analysis of 21 studies comparing the diagnostic performance of various criteria revealed the S-L index to have a sensitivity of 21%, 7 similar to that observed in the present study (26%). ECG criteria consistently underperform in obese individuals with correspondingly high rates of false negatives, particularly troublesome because of the higher prevalence of LVH in this subgroup.
14 In the context of high obesity rates in modern clinical practice, this severely limits the potential of the ECG as a screening tool for LVH; in fact, the 2007 European Society of Hypertension and European Society of Cardiology guidelines now explicitly indicate that the ECG alone should not be used to evaluate for LVH. 22 In the present study, diagnostic performance improved when using a combinatory testing strategy. The proposed LVH risk score at a threshold of 1 provides increase in sensitivity (76% [95% CI, 67-83%]) over standard S-L ECG criteria (26% [95% CI, 17-32%]), at the cost of lower specificity (55% [95% CI, 53-61%]). However, the risk score provides For example, the risk score would have very high specificity for LVH in patients with a risk score ≥2 and a very high negative predictive value (98%) for those with a score of 0. Although the sensitivity of the LVH risk score is lower compared with routine echocardiography in the general population, we observe that the sensitivity of the risk score begins to approach the screening performance of limited echocardiography (which has been reported in the range of 75% to 95%) 8, 23 when applied to subgroups where the prevalence of LVH is higher. Observed sensitivity rates for the LVH risk score were found to be 85% in those aged >50 years, 81% in those with hypertension, 83% in men, 77% in black subjects, and 74% in individuals with BMI >35. Screening these populations with echocardiography has several limitations, one of the most important being high cost 8 ; current Medicare reimbursement for a routine transthoracic echocardiography is well over $500, 24 whereas reimbursement for an ECG or for the NT-proBNP assay is one tenth as high, 25 with costs for the cTnT assay expected to stabilize at a similar level. We speculate that future cost-effectiveness analyses could reveal that a multimarker strategy offers significant cost savings over echocardiography. In addition, ultrasound imaging requires the presence of specialized infrastructure and trained personnel to perform and interpret the findings and is also subject to technical difficulties, especially in obese subjects where image quality may suffer. 26 Both NT-proBNP and cTnT have been positively associated with LV strain, renin-angiotensin-aldosterone system activation, myocardial fibrosis, and myocyte necrosis. [9] [10] [11] Serum NT-proBNP levels significantly correlate with LV wall thickness and LV mass index even in patients with significant renal disease. 9, 10 cTnT is also a marker of cardiac structural abnormalities even in the presence of hypertension and renal dysfunction. 10, 11 Despite limited use as standalone screening tests for LVH, 18,26 these 2 biomarkers have important characteristics that make them attractive complements to the ECG in a multimarker strategy: low assay costs, higher sensitivity, and better performance in obese patients. 12, 18, 27 We defined LVH using cardiac MRI, which is more accurate than echocardiography, 28 and examined a multiethnic, populationbased cohort adding to the validity and generalizability of these observations. 
Limitations
The absolute increase in AUC that we achieved is modest (0.760 to 0.798; P=0.0012); however, even small improvements in this AUC range are difficult to achieve. In Figure 2 , the receiver operator characteristic curves for the risk score and for the ECG alone converge for specificity <50%, so most of the improvement comes in the most meaningful range of specificity. In addition, the AUC, based on individual voltage components as continuous variables, is potentially misleading about the use of the ECG in diagnosing LVH in clinical practice; specific ECG criteria have low sensitivity and high specificity. In addition, the population prevalence of LVH strongly influences the positive and negative predictive values, suggesting that the risk score would be most useful in selected subpopulations, such as the obese, where LVH is more common and the test characteristics of other screening methods are less favorable. 29 The cTnT assay studied in this analysis can detect much lower concentrations (≈10-fold) than the conventional commercial assays currently available for clinical use in the United States. They are currently available in several countries and are expected to enter routine clinical use in the United States in the near future. Our population did not include enough subjects with chronic kidney disease to allow extrapolation to these subjects. Finally, this is a cross-sectional study and, therefore, is not able to address clinical outcomes.
Perspectives
Our results suggest that a testing strategy that adds NT-proBNP and cTnT (using a highly sensitive assay) to the 12-lead ECG could serve as a simple, inexpensive screen for LVH in selected populations and may help reduce unnecessary echocardiography. Further studies determining the cost-effectiveness of this approach may help clarify the clinical role of combined biomarker and ECG testing for the purpose of screening for LVH. Data collection for the study group was performed over three visits as part of the Dallas Heart Study protocol 1 : (1) a detailed in-home health survey visit, (2) a lab visit with blood and urine collection, and (3) an imaging visit that included ECG and cardiac magnetic resonance imaging (cMRI).
Sources of Funding
Cardiac MR imaging was analyzed with the following protocol: Short-axis, breath-hold ECG-gated cine magnetic resonance images were obtained from 2 comparable 1.5-T MRI systems (Philips Medical Systems, Best, Netherlands). Endocardial and epicardial borders were traced on slices obtained from the apex to the base of the LV to measure cavity volume and wall mass. Measurements from each slice were summed using the method of discs, and the papillary muscles were included in the myocardial mass. Inter-observer difference for LV mass was 5.8±3.5%, intra-observer was 7.1±6.0%, and inter-scan variability was 2.9±7.5%.
Electrocardiograms were obtained and analyzed with the following protocol: Standard 12-lead ECGs were recorded at 25mm/s and 1mV/cm standardization with a sampling rate of 0.5 kHz. The analog potential was digitized at 4 kHz at the level of the patient and with a line frequency filter to reduce 60 Hz electrical interference. Output was obtained by averaging 10 consecutive digital values. Voltage measurements were obtained electronically using median voltages from an aligned group of all beats from each lead, allowing better noise reduction than voltage means, which are more susceptible to skewing by outlier beats. Two DHS investigators blinded to demographic and clinical information reviewed each ECG to verify the computer identified parameters and provide a clinical interpretation.
Biomarkers were measured using the following protocol: Venous blood samples were collected into EDTA tubes, refrigerated at 4°C for 4 hours or less, centrifuged, and the plasma removed and stored at −70°C. NT-proBNP was measured from these stored/frozen blood samples using a well validated, commercially available assay (Roche Diagnostics). 2 cTnT was also measured from these samples using the Elecsys-2010 Troponin T hs STAT platform (Roche Diagnostics), with a minimal detectable concentration (MDC) of 0.003 mcg/L. The interassay coefficient of variability of this assay is 8% at 0.01 mcg/L and 2.5% at 0.1 mcg/L. Intraassay coefficient of variability was 5% at 0.01 mcg/L and 1% at 0.1 mcg/L. 3 Variable definitions: For ROC curve analyses, total voltage from S in V1 plus the maximum R voltage from V5 or V6 was used as a continuous exposure variable. Race/ethnicity were self-reported, the presence of hypertension was determined by either confirmed use of antihypertensive medications, an average systolic blood pressure ≥140 mmHg, or an average diastolic blood pressure ≥90 mmHg during three separate measurements at the final study visit.15 Finally, BMI was partitioned into categories based on NHLBI guidelines: normal weight (BMI 18.5-24.9 kg/m2), overweight (BMI 25-29.9 kg/m2), Class 1 obesity (BMI 30-34.9 kg/m2), and Class 2-3 obesity (BMI >35 kg/m2). Parentheses indicate 95% confidence interval. Table S3 . Patient characteristics stratified by LVH risk score using the C/S Index as the electrocardiographic criteria in the LVH risk score.
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